carcinogenicity testing would be most effective in providing information to assist risk managers, given the incomplete scientific understanding of chemical carcinogenesis in rodents and humans.

Efforts to improve cancer risk assessment have resulted in the development of a mathematical dose-response model, called the two-stage model, that is based on a two-stage paradigm for the biologic phenomena thought to be associated with carcinogenesis. This paradigm is based on the relationship between tumor incidence and age, which suggests that at least two critical cellular changes are necessary for the development of many nonhereditary tumors. Current evidence suggests that some tumors might require more than two critical events to be expressed as human cancer. More complex models might be needed to describe multistage carcinogenesis accurately; however, it is hoped that the two-stage model will provide more accurate estimates of the cancer potency of chemicals that the multistage models currently in use by regulatory agencies.

Applying the two-stage model requires more extensive biologic data than current procedures; and because its feasibility as a tool for routine regulatory use has been questioned CRAM chose as its second task to evaluate the data needs and regulatory applicability of two-stage models of carcinogenesis. The committee considered several applications of the two-stage model to rodent carcinogens with different mechanisms of action and different quantities of available data. The committee noted that numerous assumptions were required to apply the model in each case. Assumptions must be made about mechanisms of action, appropriate target cells, time dependence, and the shape of the dose-response relationship. Extensive data would have to be obtained to reduce the current uncertainty in these assumptions. In fact, for very few chemicals are data sufficient to support the use of this model.

By studying specific application of the two-stage model, the committee determined that when different forms of the model are consistent with a particular data set, risk estimates can differ by several orders of magnitude. Therefore, the committee concluded that even if an agent's

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.

Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 9

EXECUTIVE SUMMARY 9
original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the
retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
carcinogenicity testing would be most effective in providing information to
assist risk managers, given the incomplete scientific understanding of chemical
carcinogenesis in rodents and humans.
THE TWO-STAGE MODEL OF CARCINOGENESIS
Efforts to improve cancer risk assessment have resulted in the development
of a mathematical dose-response model, called the two-stage model, that is
based on a two-stage paradigm for the biologic phenomena thought to be
associated with carcinogenesis. This paradigm is based on the relationship
between tumor incidence and age, which suggests that at least two critical
cellular changes are necessary for the development of many nonhereditary
tumors. Current evidence suggests that some tumors might require more than
two critical events to be expressed as human cancer. More complex models
might be needed to describe multistage carcinogenesis accurately; however, it is
hoped that the two-stage model will provide more accurate estimates of the
cancer potency of chemicals that the multistage models currently in use by
regulatory agencies.
Applying the two-stage model requires more extensive biologic data than
current procedures; and because its feasibility as a tool for routine regulatory
use has been questioned CRAM chose as its second task to evaluate the data
needs and regulatory applicability of two-stage models of carcinogenesis. The
committee considered several applications of the two-stage model to rodent
carcinogens with different mechanisms of action and different quantities of
available data. The committee noted that numerous assumptions were required
to apply the model in each case. Assumptions must be made about mechanisms
of action, appropriate target cells, time dependence, and the shape of the dose-
response relationship. Extensive data would have to be obtained to reduce the
current uncertainty in these assumptions. In fact, for very few chemicals are
data sufficient to support the use of this model.
By studying specific application of the two-stage model, the committee
determined that when different forms of the model are consistent with a
particular data set, risk estimates can differ by several orders of magnitude.
Therefore, the committee concluded that even if an agent's